Akorn, Inc. (AKRX) Tops Q4 EPS by 1c
Tweet
Share
E-mailGet Alerts AKRX Hot Sheet
Price: $0.09 --0%
Financial Fact:
Interest expense, net: -10.34M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Financial Fact:
Interest expense, net: -10.34M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Join SI Premium – FREE
Akorn, Inc. (NASDAQ: AKRX) reported Q4 EPS of $0.13, $0.01 better than the analyst estimate of $0.12. Revenue for the quarter came in at $71.5 million versus the consensus estimate of $69.42 million.
Pipeline update:
The Company has 56 ANDAs filed with the FDA with a combined annual addressable IMS market size of approximately $5.8 billion. The Company has completed development work on 10 additional products with a combined annual addressable IMS market size of approximately $0.3 billion and expects to file these products with the FDA shortly.
For earnings history and earnings-related data on Akorn, Inc. (AKRX) click here.
Pipeline update:
The Company has 56 ANDAs filed with the FDA with a combined annual addressable IMS market size of approximately $5.8 billion. The Company has completed development work on 10 additional products with a combined annual addressable IMS market size of approximately $0.3 billion and expects to file these products with the FDA shortly.
For earnings history and earnings-related data on Akorn, Inc. (AKRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
- Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
